SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), an organization centered on creating and delivering engineered cells as medicines, right now introduced that it’s going to webcast its displays at two investor conferences in September. The displays will characteristic a business overview and replace by Steve Harr, Sana’s President and Chief Executive Officer.
- Sana will current at the Morgan Stanley 20th Annual Global Healthcare Conference at 2:55 p.m. ET on Tuesday, September 13, 2022.
- Sana will current at the Jefferies Cell and Genetic Medicine Summit at 2:00 p.m. ET on Thursday, September 29, 2022.
The webcasts will likely be accessible on the Investor Relations web page of Sana’s web site at https://sana.com/. A replay of every presentation will likely be obtainable at the identical location for 30 days following the corresponding convention.
About Sana Biotechnology
Sana Biotechnology, Inc. is concentrated on creating and delivering engineered cells as medicines for sufferers. We share a imaginative and prescient of repairing and controlling genes, changing lacking or broken cells, and making our therapies broadly obtainable to sufferers. We are a passionate group of individuals working collectively to create an everlasting firm that adjustments how the world treats illness. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For extra details about Sana Biotechnology, please go to https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press launch accommodates forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) throughout the that means of the federal securities legal guidelines, together with these associated to the Company’s imaginative and prescient; the Company’s participation within the Morgan Stanley 20th Annual Global Healthcare Conference and the Jefferies Cell and Genetic Medicine Summit; and the subject material of the Company’s displays at these conferences. All statements aside from statements of historic information contained on this press launch, together with, amongst others, statements relating to the Company’s technique, expectations, money runway and future monetary situation, future operations, and prospects, are forward-looking statements. In some instances, you may determine forward-looking statements by terminology similar to “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and different comparable expressions which are predictions of or point out future occasions and future traits, or the damaging of those phrases or different comparable terminology. The Company has based mostly these forward-looking statements largely on its present expectations, estimates, forecasts and projections about future occasions and monetary traits that it believes might have an effect on its monetary situation, outcomes of operations, business technique and monetary wants. In gentle of the numerous uncertainties in these forward-looking statements, you shouldn’t depend upon forward-looking statements as predictions of future occasions. These statements are topic to dangers and uncertainties that would trigger the precise outcomes to fluctuate materially, together with, amongst others, the dangers inherent in drug growth similar to these related to the initiation, value, timing, progress and outcomes of the Company’s present and future analysis and growth applications, preclinical and medical trials, in addition to the financial, market and social disruptions due to the continued COVID-19 public well being disaster. For an in depth dialogue of the danger components that would have an effect on the Company’s precise outcomes, please refer to the danger components recognized within the Company’s SEC experiences, together with however not restricted to its Quarterly Report on Form 10-Q dated August 4, 2022. Except as required by legislation, the Company undertakes no obligation to replace publicly any forward-looking statements for any motive.
Investor Relations & Media:
Nicole Keith
[email protected]
[email protected]
